Cargando…
Paths for Improving Bevacizumab Available in 2018: The ADZT Regimen for Better Glioblastoma Treatment
During glioblastoma treatment, the pharmaceutical monoclonal antibody to vascular endothelial growth factor A, bevacizumab, has improved the quality of life and delayed progression for several months, but has not (or only marginally) prolonged overall survival. In 2017, several dramatic research pap...
Autor principal: | Kast, Richard E. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6313620/ https://www.ncbi.nlm.nih.gov/pubmed/30274295 http://dx.doi.org/10.3390/medsci6040084 |
Ejemplares similares
-
Augmentation of 5-Aminolevulinic Acid Treatment of Glioblastoma by Adding Ciprofloxacin, Deferiprone, 5-Fluorouracil and Febuxostat: The CAALA Regimen
por: Kast, Richard E., et al.
Publicado: (2018) -
The OSR9 Regimen: A New Augmentation Strategy for Osteosarcoma Treatment Using Nine Older Drugs from General Medicine to Inhibit Growth Drive
por: Kast, Richard E.
Publicado: (2023) -
Methylxanthines: Potential Therapeutic Agents for Glioblastoma
por: Pérez-Pérez, Daniel, et al.
Publicado: (2019) -
Finding Common Ground: Environmental Ethics, Social Justice, and a Sustainable Path for Nature-Based Health Promotion
por: Jennings, Viniece, et al.
Publicado: (2016) -
Towards Better CARE for Superficial Fungal Infections: A Consultation Guide for the Community Pharmacy
por: Parinyarux, Pantira, et al.
Publicado: (2022)